Celularity Inc. has reported its actual financial results for the year ended December 31, 2024. The company's total net revenues increased significantly to $54.220 million, compared to $22.771 million in the previous year. This growth was driven by a rise in product sales, which reached $35.336 million, up from $13.149 million the previous year. Additionally, revenues from licenses, royalties, and other sources grew to $13.744 million from $4.181 million. Despite the increase in revenues, Celularity Inc. continues to face financial challenges, as indicated by its accumulated deficit of $899.683 million, compared to $841.791 million the previous year. These results highlight the company's ongoing efforts to enhance its revenue streams through increased product sales and licensing agreements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.